{"id":63,"date":"2024-10-06T05:40:36","date_gmt":"2024-10-06T05:40:36","guid":{"rendered":"https:\/\/canisleep.com\/?p=63"},"modified":"2024-10-07T04:54:40","modified_gmt":"2024-10-07T04:54:40","slug":"patient-voices-drive-push-for-better-idiopathic-hypersomnia-care","status":"publish","type":"post","link":"https:\/\/canisleep.com\/index.php\/2024\/10\/06\/patient-voices-drive-push-for-better-idiopathic-hypersomnia-care\/","title":{"rendered":"Patient Voices Drive Push for Better Idiopathic Hypersomnia Care"},"content":{"rendered":"\n

<\/p>\n\n\n\n

A new report illuminates the real-world experiences and treatment needs of individuals with idiopathic hypersomnia.<\/h1>\n\n\n\n
\n\n\n\n

Summary: <\/strong>A new report titled \u201cVoice of the Patient\u201d on idiopathic hypersomnia (IH), published by the Sleep Consortium and global sleep-related advocacy organizations, highlights the real-world experiences and unmet treatment needs of individuals with IH. The report, based on feedback from an externally led patient-focused drug development (EL-PFDD) meeting and survey responses from 811 individuals across 21 countries, aims to guide research, regulatory decisions, and the development of new therapies for IH. The report has been submitted to the FDA and emphasizes the prolonged diagnostic delays and inadequacies in current treatment options for IH, calling for action to address these challenges.<\/p>\n\n\n\n

Key Takeaways:<\/strong><\/p>\n\n\n\n

    \n
  1. Diagnostic Delays and Treatment Gaps:<\/strong>\u00a0The report reveals that individuals with idiopathic hypersomnia experience lengthy diagnostic delays, with an average of 14 years from symptom onset to diagnosis, and that current treatments remain largely ineffective for many patients.<\/li>\n\n\n\n
  2. Patient Advocacy and Research Focus:\u00a0<\/strong>The \u201cVoice of the Patient\u201d report, part of the Illuminate Hypersomnia initiative, seeks to amplify the lived experiences of those with IH, serving as a resource for regulators, healthcare professionals, and pharmaceutical developers to prioritize more effective therapies and improved care.<\/li>\n\n\n\n
  3. Global Collaboration for IH Awareness:<\/strong>\u00a0Supported by various international patient organizations and pharmaceutical companies, the report aims to foster ongoing research and educational efforts, including upcoming conferences and events, to raise awareness and improve outcomes for people living with idiopathic hypersomnia.<\/li>\n<\/ol>\n\n\n\n
    \n\n\n\n

    The Sleep Consortium, in partnership with a coalition of global sleep-related patient advocacy organizations, announced the publication of the \u201cVoice of the Patient\u201d report<\/a> on idiopathic hypersomnia (IH). <\/p>\n\n\n\n

    This document, a product of the Illuminate Hypersomnia initiative<\/a>, offers a view of the lived experiences and treatment aspirations of individuals with IH. <\/p>\n\n\n\n

    The \u201cVoice of the Patient\u201d report is based on feedback collected through an externally led patient-focused drug development meeting held on April 11, 2024, and a survey that attracted 811 responses from people living in 21 countries. The report aims to shed light on the challenges faced by those living with IH, providing insights for regulators, pharmaceutical developers<\/a>, researchers, healthcare professionals, and policymakers.<\/p>\n\n\n\n

    Amplifying IH Voices<\/h2>\n\n\n\n

    The Illuminate Hypersomnia initiative was designed to amplify the voices of individuals impacted by IH. By exploring their personal narratives, current management strategies, and unmet treatment needs, the report seeks to guide future research and therapy development. It was a parallel effort to the US Food and Drug Administration\u2019s (FDA) patient-focused drug development initiative<\/a> to more systematically gather patients\u2019 perspectives on their conditions and available therapies to treat them. <\/p>\n\n\n\n

    The IH report has been submitted to the FDA for posting on the agency\u2019s webpage of condition-specific meeting reports<\/a>.<\/p>\n\n\n\n

    \u201cFor the first time, a 360-degree exposition of the lived experience of IH is portrayed with honesty and vulnerability on a scale never before seen, heard, or published,\u201d says Claire Wylds-Wright, co-founder and chief experience officer of the Sleep Consortium, in a release. \u201cThis timely report is unequivocal in its individual and collective proclamation that living for years with a diagnosis, and additional years without adequate treatment for IH can wreak havoc on every aspect of an individual\u2019s life.<\/p>\n\n\n\n

    \u201cThis community statement of what it\u2019s like to live with IH demands a call to action that those in positions of responsibility and opportunity should respond to accordingly. Read this report, digest it, share it. And help unburden those who have been courageous enough to tell us what they need.\u201d<\/p>\n\n\n\n

    Key findings from the report highlight:<\/strong><\/p>\n\n\n\n